Key Points Teva reported Q1 earnings, beating Wall Street's EPS expectations. The company raised its full-year guidance as margins expand. 10 stocks we like better than Teva Pharmaceutical Industries › Shares of Teva Pharmaceutical(NYSE: TEVA) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m. ET and was up as much as 9.5% earlier in the day. The leg up comes as the S&P 500 is up 0.4% and the Nasdaq Composite is losing 0.1% on the day so far. The Israel-based pharmaceutical company reported strong Q1 earnings today and raised its full-year profit guidance. Earnings beat despite revenue miss Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's target of $0.48. The company missed on sales, however, reporting $3.89 billion for the quarter when $4 billion was expected. Still, the company's margins are expanding, reaching 48.2% in the quarter, compared to 46.4% a year ago. The company pointed to higher-margin specialty drugs representing a larger portion of overall sales this quarter. One of these drugs, Austedo, which is used to treat movement disorders, continued its strong performance with worldwide revenue of $411 for the quarter, up 39%, compared to the same period last year.Image source: Getty Images Teva raises guidance Teva raised its fiscal 2025 adjusted EPS guidance from a range of $2.35 to $2.65 to a new range of $2.45 to $2.65. The new midpoint exceeds the consensus estimate of $2.55. CEO Richard Francis emphasized that Teva is now entering the "Acceleration Phase" of its "Pivot to Growth Strategy." "We're accelerating innovative growth and strengthening our generics business, while streamlining our operations, sharpening our business, and optimizing processes," Francis stated. These efficiency measures, combined with the company's product growth, appear to be resonating with investors. The company appears to be delivering on its growth plan. Considering its reasonable valuation, I think the stock is a good pick. Should you invest $1,000 in Teva Pharmaceutical Industries right now? Before you buy stock in Teva Pharmaceutical Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $613,546!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $695,897!* Now, it’s worth notingStock Advisor’s total average return is893% — a market-crushing outperformance compared to162%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » Story Continues *Stock Advisor returns as of May 5, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Teva Pharmaceutical Stock Is Soaring Today was originally published by The Motley Fool View Comments
Why Teva Pharmaceutical Stock Is Soaring Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...